Literature DB >> 14718405

Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure.

Tae-Joon Cha1, Joachim R Ehrlich, Liming Zhang, Yan-Fen Shi, Jean-Claude Tardif, Tack Ki Leung, Stanley Nattel.   

Abstract

BACKGROUND: Congestive heart failure (CHF) downregulates atrial transient outward (I(to)), slow delayed rectifier (I(Ks)), and L-type Ca(2+) (I(Ca,L)) currents and upregulates Na(+)-Ca(2+) exchange current (I(NCX)) (ionic remodeling) and causes atrial fibrosis (structural remodeling). The relative importance of ionic versus structural remodeling in CHF-related atrial fibrillation (AF) is controversial. METHODS AND
RESULTS: We measured hemodynamic and echocardiographic parameters, mean duration of burst pacing-induced AF (DAF), and atrial-myocyte ionic currents in dogs with CHF induced by 2-week ventricular tachypacing (240 bpm), CHF dogs allowed to recover without pacing for 4 weeks (REC), and unpaced controls. Left ventricular ejection fraction averaged 58.6+/-1.2% (control), 36.2+/-2.3% (CHF, P<0.01), and 57.9+/-1.6% (REC), indicating full hemodynamic recovery. Similarly, left atrial pressures were 2.2+/-0.3 (control), 13.1+/-1.5 (CHF), and 2.4+/-0.4 (REC) mm Hg. CHF reduced I(to) density by approximately 65% (P<0.01), decreased I(Ca,L) density by approximately 50% (P<0.01), and diminished I(Ks) density by approximately 40% (P<0.01) while increasing I(NCX) density by approximately 110% (P<0.05). In REC, all ionic current densities returned to control values. DAF increased in CHF (1132+/-207 versus 14.3+/-8.8 seconds, control) and remained increased with REC (1014+/-252 seconds). Atrial fibrous tissue content also increased in CHF (2.1+/-0.2% for control versus 10.2+/-0.7% for CHF, P<0.01), with no recovery observed in REC (9.4+/-0.8%, P<0.01 versus control, P=NS versus CHF).
CONCLUSIONS: With reversal of CHF, there is complete recovery of ionic remodeling, but the prolonged-AF substrate and structural remodeling remain. This suggests that structural, not ionic, remodeling is the primary contributor to AF maintenance in experimental CHF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718405     DOI: 10.1161/01.CIR.0000109501.47603.0C

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  52 in total

1.  Cardiac resynchronisation therapy in chronic atrial fibrillation: impact on left atrial size and reversal to sinus rhythm.

Authors:  P Kiès; C Leclercq; G B Bleeker; C Crocq; S G Molhoek; C Poulain; L van Erven; M Bootsma; K Zeppenfeld; E E van der Wall; J-C Daubert; M J Schalij; J J Bax
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

Review 2.  Atrial fibrillation: basic mechanisms, remodeling and triggers.

Authors:  Akiko Shiroshita-Takeshita; Bianca J J M Brundel; Stanley Nattel
Journal:  J Interv Card Electrophysiol       Date:  2005-09       Impact factor: 1.900

3.  Differential expression of potassium channels and abnormal conduction in experimental tachycardia-induced heart failure.

Authors:  Christoph Birner; Oliver Husser; Andreas Jeron; Munhie Rihm; Sabine Fredersdorf; Markus Resch; Peter Schmid; Dierk Endemann; Günter Riegger; Andreas Luchner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-07       Impact factor: 3.000

4.  Chronic heart failure and the substrate for atrial fibrillation.

Authors:  Arun Sridhar; Yoshinori Nishijima; Dmitry Terentyev; Mahmood Khan; Radmila Terentyeva; Robert L Hamlin; Tomohiro Nakayama; Sandor Gyorke; Arturo J Cardounel; Cynthia A Carnes
Journal:  Cardiovasc Res       Date:  2009-06-30       Impact factor: 10.787

5.  Circulating fibrosis biomarkers and risk of atrial fibrillation: The Cardiovascular Health Study (CHS).

Authors:  Michael A Rosenberg; Marlena Maziarz; Alex Y Tan; Nicole L Glazer; Susan J Zieman; Jorge R Kizer; Joachim H Ix; Luc Djousse; David S Siscovick; Susan R Heckbert; Kenneth J Mukamal
Journal:  Am Heart J       Date:  2014-02-26       Impact factor: 4.749

Review 6.  Novel approaches for pharmacological management of atrial fibrillation.

Authors:  Joachim R Ehrlich; Stanley Nattel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  Diclofenac, a Non-steroidal Anti-inflammatory Drug, Inhibits L-type Ca Channels in Neonatal Rat Ventricular Cardiomyocytes.

Authors:  Oleg V Yarishkin; Eun Mi Hwang; Donggyu Kim; Jae Cheal Yoo; Sang Soo Kang; Deok Ryoung Kim; Jae-Hee-Jung Shin; Hye-Joo Chung; Ho-Sang Jeong; Dawon Kang; Jaehee Han; Jae-Yong Park; Seong-Geun Hong
Journal:  Korean J Physiol Pharmacol       Date:  2009-12-31       Impact factor: 2.016

8.  Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG.

Authors:  B F McBride; T Yang; D M Roden
Journal:  Pharmacogenomics J       Date:  2009-02-10       Impact factor: 3.550

9.  Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1.

Authors:  Dolkun Rahmutula; Gregory M Marcus; Emily E Wilson; Chun-Hua Ding; Yuanyuan Xiao; Agnes C Paquet; Rebecca Barbeau; Andrea J Barczak; David J Erle; Jeffrey E Olgin
Journal:  Cardiovasc Res       Date:  2013-04-23       Impact factor: 10.787

Review 10.  Comorbidity of atrial fibrillation and heart failure.

Authors:  Liang-Han Ling; Peter M Kistler; Jonathan M Kalman; Richard J Schilling; Ross J Hunter
Journal:  Nat Rev Cardiol       Date:  2015-12-10       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.